AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
AstraZeneca beats revenue, profit estimates on resilient demand
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
U.S. FDA approves AstraZeneca`s Tagrisso-chemo combo
Kairos Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105
AstraZeneca is tossing a little cash towards Allorion Therapeutics to pick up a friend for approved lung cancer med Tagrisso.
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a prespecified exploratory analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of chemotherapy demonstrated a 42% improvement in central nervous system (CNS) progression-free survival (PFS), compared to TAGRISSO alone for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) and brain metastases at baseline, representing 40% of patients in the trial, as assessed by blinded independent central review (BICR).
A drug combination from Johnson & Johnson outperformed AstraZeneca’s Tagrisso in slowing the worsening of newly diagnosed lung cancer. But it’ll take more than a tumor progression win to dethrone the EGFR king.
AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Johnson & Johnson said that its combination treatment staved off cancer progression for longer than AstraZeneca’s blockbuster Tagrisso as a first option for patients with a form of advanced lung cancer.